首页
登录
职称英语
The "issues" reported were unthinkable. The physician who enrolled the most
The "issues" reported were unthinkable. The physician who enrolled the most
游客
2025-04-16
56
管理
问题
The "issues" reported were unthinkable. The physician who enrolled the most patients in the study, an Alabama weight-loss doctor, allegedly forged scores of signatures, enrolling "volunteers" every few minutes.
By the time of the FDA review, she was under criminal investigation. (She’s now in federal prison. ) Another key researcher had been put on probation by the California medical board for gross negligence. He was arrested shortly after the study ended, when police, called to his home on a domestic violence complaint, found him with a bag of cocaine and waving a loaded gun at imaginary people. The study was so riddled with fraud and error that FDA reviewers decided it was useless.
Yet Dr. Ross says he was told to reveal nothing about those problems to the advisory board, which recommended that the drug be approved. Later, he says, he was pressured to soften his report about Ketek’s liver toxicity to gain approval of higher-ups.
Six million Americans have now used the drug, including hundreds of infants in a clinical trial designed to test Ketek’s effectiveness against ear infections. "How does one justify balancing the risk of fatal liver failure against one day less of ear pain?" One FDA scientist, Rosemary Johann-Liang, protested—to no avail—in a memo to her superiors. Most ear infections clear up in a few days on their own, she says.
The agency says the controversy is overblown. "There was enough good, solid scientific data to make that decision. " Says FDA spokeswoman Julie Zawisza, pointing to what appeared to be a history of safe use of Ketek in other countries. Ketek has now been linked to 18 deaths and at least 134 cases of liver damage, according to an independent analysis u-sing FDA data. The real toll, some researchers say, may be far greater.
Last October the FDA sent a warning letter to Sanofi-Aventis, Ketek’s maker, accusing the company of knowingly presenting compromised data to the agency, a charge the company denies. "We were not aware of the fraud," says spokeswoman Melissa Feltmann. "It was not until the FDA’s criminal investigators uncovered it that we became aware of it. "
The question remains, What did the FDA and the drugmaker know about the fake safety data, and when?
Congressmen John Dingell and Bart Stupak, both Michigan Democrats, are investigating that mystery right now in Congressional hearings.
"Unfortunately," Stupak says, "the truth comes too late for some victims. " [br] The author obviously believes that, in the incident, FDA failed to______.
选项
A、compensate the victims
B、take immediate actions
C、control the whole situation
D、stick to its moral principles
答案
B
解析
考查推断能力。根据最后一段: “Unfortunately,”Stupak says,“the truth comes too late for some victims.”据此可知食品与药品管理局没有及时把这个消息告诉大众,所以B项符合题意。
转载请注明原文地址:https://www.tihaiku.com/zcyy/4040273.html
相关试题推荐
The"issues"reportedwereunthinkable.Thephysicianwhoenrolledthemost
The"issues"reportedwereunthinkable.Thephysicianwhoenrolledthemost
The"issues"reportedwereunthinkable.Thephysicianwhoenrolledthemost
The"issues"reportedwereunthinkable.Thephysicianwhoenrolledthemost
LewisThomaswasbornin1913inFlushing,NewYorktoafamilyphysicianan
Althoughitrulesthattheseisnoconstitutionalrighttophysician-assistedsu
Thepollutionquestionaswellasseveralotherissuesisgoingtobediscussed
In1998,aBelgianstudentnamedSachaKleinleftBrusselsandenrolledasa
In1998,aBelgianstudentnamedSachaKleinleftBrusselsandenrolledasa
In1998,aBelgianstudentnamedSachaKleinleftBrusselsandenrolledasa
随机试题
[originaltext]M:Idon’tknowwhatIcouldhavedonetomakeBobsomadatme.
旅游需求价格弹性系数是指()。A.旅游需求量变化百分数与旅游产品价格变化百分
某护士采用焦虑自评量表,对50名肾移植术后患者进行测评。结果:该组患者量表得分为
中国证监会自受理期货公司资产管理业务试点资格申请之日起()个月内,作出批准或者
A.75%乙醇 B.2%过氧乙酸 C.0.5%碘伏 D.10mg/L二溴海
目前各国证券市场广泛采用的交收方式是()。 A.滚动交收B.会计日交收
固定桥粘固一段时期后出现冷热刺激痛,最可能的原因是A.基牙继发龋B.牙周咬合创伤
关于数据可视化的说法,正确的有()。A.数据可视化借助图形化手段清晰有效地传
中小型形状复杂的装配件表面的防锈油脂,其初步清洗的方法是()。A:清洗液浸洗
统计调查表法的应用程序包括:①明确收集数据和资料的目的;②确定需要收集的质量数据
最新回复
(
0
)